Skip to content
Study details
Enrolling now

Suvorexant Trial for AUD and PTSD

Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
NCT IDNCT06679062ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

76

Study length

about 12 months

Ages

21–65

Locations

2 sites in CA, TX

What this study is about

This trial is testing if suvorexant (SUV) can reduce insomnia in adults with post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD). Participants will receive either a placebo or SUV, followed by a two-week abstinence period from alcohol. They will track their symptoms using daily diaries and attend clinic visits to assess outcomes.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Suvorexant

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

suvorexant

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change in Insomnia Severity Index (ISI) score from baseline to Day 14.

Secondary: Change in PTSD total symptom severity score as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) from baseline to Day 14.

Body systems

Psychiatry / Mental Health